Search Results

Showing results 1301 - 1310 for leonard

Open radial artery harvesting better preserves endothelial function compared to the endoscopic approach. | Pathology & Laboratory Medicine

... MRosaria, Leonard J, Rahouma M, Di Franco A, He G-W, Girardi LN, Tranbaugh RF, Di Lorenzo A Journal...

https://pathology.weill.cornell.edu/research/publications/open-radial-artery-harvesting-better-preserves-endothelial-function-compared

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. | Pathology & Laboratory Medicine

..., Leonard JP, Cerchietti L Journal Leuk Lymphoma Volume 59 Issue 1 Pagination 256-258 Date Published 2018...

https://pathology.weill.cornell.edu/research/publications/eif4e-inhibitor-ribavirin-potential-antilymphoma-therapeutic-early-clinical

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. | Pathology & Laboratory Medicine

..., Melnick A, Coleman M, Leonard JP Journal Clin Lymphoma Myeloma Leuk Volume 10 Issue 3 Pagination 192...

https://pathology.weill.cornell.edu/research/publications/response-second-line-therapy-defines-potential-cure-patients-recurrent-diffuse

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. | Pathology & Laboratory Medicine

..., Coleman M, Goldsmith SJ, Leonard JP Journal Leuk Lymphoma Volume 49 Issue 4 Pagination 719-26 Date...

https://pathology.weill.cornell.edu/research/publications/fdg-pet-prediction-splenectomy-findings-patients-known-or-suspected-lymphoma

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. | Pathology & Laboratory Medicine

... Type Journal Article Year of Publication 2004 Authors Leonard JP, Coleman M, Ketas JC, Chadburn...

https://pathology.weill.cornell.edu/research/publications/epratuzumab-humanized-anti-cd22-antibody-aggressive-non-hodgkins-lymphoma

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. | Pathology & Laboratory Medicine

..., Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP...

https://pathology.weill.cornell.edu/research/publications/dose-attenuated-radioimmunotherapy-tositumomab-and-iodine-131-tositumomab

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. | Pathology & Laboratory Medicine

... 2003 Authors Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ...

https://pathology.weill.cornell.edu/research/publications/phase-iii-trial-epratuzumab-humanized-anti-cd22-antibody-indolent-non-hodgkins

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. | Pathology & Laboratory Medicine

... Article Year of Publication 2005 Authors Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR...

https://pathology.weill.cornell.edu/research/publications/combination-antibody-therapy-epratuzumab-and-rituximab-relapsed-or-refractory

Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. | Pathology & Laboratory Medicine

... 2006 Authors Ruan J, Hyjek E, Kermani P, Christos PJ, Hooper AT, Coleman M, Hempstead B, Leonard JP...

https://pathology.weill.cornell.edu/research/publications/magnitude-stromal-hemangiogenesis-correlates-histologic-subtype-non-hodgkins

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. | Pathology & Laboratory Medicine

... FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D, Knowles DM, Wang YL Journal Leukemia...

https://pathology.weill.cornell.edu/research/publications/tyrosine-kinase-inhibition-diffuse-large-b-cell-lymphoma-molecular-basis

Showing results 1301 - 1310 for leonard